Assessment of the Effect of Albumin Compared with Placebo on Functional Outcome in Subjects’ Post Brain Infarct in the Middle Cerebral Artery Territory in Patients Referred to Golestan Hospital of Ahvaz

Document Type : Original Article

Authors

1 Department of Neurology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Department of Neurology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Abstract

Background and Objective: Stroke  is  the  third common  cause  of  mortality  and the most  common  cause  of  morbidity  in  elderly persons. Albumin is a treatment indicated for post-stroke recovery. The  aim  of  this  study  was  to  investigate  the  effect  of albumin on the functional outcome  at the end of the third month in post-stroke subjects.
Subjects and Methods: This is a double-blinded, placebo controlled, randomized study of 139 subjects included within 5 hr of stroke onset. All subjects were given either albumin (20%) or placebo (isovolumic normal saline) with at a dose of 1g/Kg IV infusion over 2 hr. Barthel index score and modified Rankin scale were used for assessment at baseline and at 3 months.
Results: Albumin administration had significant effect in reduction of  length of  hospitality (P<0.05). However, there was no significant difference in mortality rate between albumin and placebo group (P>0.05). Subjects in the treatment group showed a significant  difference  in the  rank of MRS: 61.6 vs 78.2 in the  placebo  group and mean change  of  the  Barthel  Index:  38  versus  28, respectively. The time from stroke onset to albumin therapy initiation is effective in clinical improvement of patients (P<0.05).
Conclusion: It seems that administration of albumin has significant effect in improving the clinical function of the patients and reduces the length of hospitalization, especially in smaller strokes and when treatment is initiated early.   
 

Keywords

References

1-Adamsadvitors, mauricevhector,allen.H.Reppe, cerebrovascular disease. Principle of  Neurology. 2009; 511-2.
2-Werner H, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti,D, Larrue V, et al. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. N Engl J Med 2008;359:1317- 29:1317-29.
3-Mahoney FI, Barthel DW. Functional evaluation: the barthel index. Md State Med J 1965:14:61-5. 
4-Dziedzic T, Slowik A, Szczudlik A. Serum albumin level as a predictor of ischemic stroke outcome. Stroke 2004 Jun;35(6):e156-8.
5-Dávalos A, Ricart W, Gonzalez-Huix F, Soler S, Marrugat J, Molins A, et al. Effect of malnutrition after acute stroke on clinical outcome. Stroke 1996;27(6):1028–32.
6-Franch-Arcas G. The meaning of hypoalbuminemia in clinical practice. Clin Nutr 2001;20:265–9.
7-Belayev L, Pinard E, Nallet H, Seylaz J, Liu Y, Riyamongkol P, et al. Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses. Stroke 2002;33(4):1077–84.
8-Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001;32(2):553–60 
9-Reinhart WH, Nagy C. Albumin affects erythrocyte aggregation and sedimentation. Eur J Clin Invest 1995;25(7):523–8.
10-Halliwell B. Albumin--an important extracellular antioxidant? Biochem Pharmacol 1998;37(4):569–71.
11-Hallenbeck JM, Dutka AJ, Tanishima T, Kochanek PM, Kumaroo KK, Thompson CB, et al. Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period. Stroke 1986;17(2):246–53.
12-Belayev L, Busto R, Zhao W, Clemens JA, Ginsberg MD. Effect of delayed albumin hemodilution on infarction volume and brain edema after transient middle cerebral artery occlusion in rats. J Neurosurg 1997;87(4):595–601
13-Gillum RF, Ingram DD, Makuc DM. Relation between serum albumin concentration and stroke incidence and death: the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1994;140(10):876-88.
14-Herrmann FR, Safran C, Levkoff SE, Minaker KL. Serum albumin level on   admission as a predictor of death, length of stay, and read mission. Arch Intern  Med 1992;152(1):125-30.
15-Dziedzic T, Pera J, Slowik A, Gryz-Kurek EA, Szczudlik A. Hypoalbuminemia in acute ischemic stroke patients: frequency and correlates. Eur J Clin Nutr 2007;61(11):1318-22.
16- Famakin B, Weiss P, Hertzberg V, McClellan W, Presley R, Krompf K, et al.  Hypoalbuminemia predicts acute stroke mortality: Paul Coverdell Georgia Stroke Registry. J Stroke Cerebrovasc Dis 2010;19(1):17-22.
17-Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD. Human albumin therapy of acute                                                                                                                                                                                                                                                                                                                                                                                                                        ischemic stroke: marked neuroprotective efficacy at moderat doses and with a broad therapeutic window. Stroke 2001;32(2):553-60.
18-Gillum RF. Assessment of serum albumin concentration as a risk factor for stroke and coronary disease in African Americans and whites. J Natl Med Assoc 2000;92(1):3-9.
19-Cho YM, Choi IS, Bian RX, Kim JH, Han JY, Lee SG. Serum albumin at admission for prediction of functional outcome in  ischemic stroke patients. Neurol Sci 2008;29(6):445–9.
Jundishapur Scientific Medical Journal
Volume 13, Issue 3 - Serial Number 90
September and October 2014
Pages 365-373

Files

History

  • Receive Date: 28 December 2013
  • Revise Date: 26 February 2014
  • Accept Date: 27 April 2014

Share

How to cite

Statistics